Drug intelligence / Profile preview

MVP-106

Development stage: Preclinical
Lead developer: Multiverse Pharma
Administration: Intravenous

Overview

MVP-106 is a preclinical-stage blood-brain barrier (BBB) shuttle developed by Multiverse Pharma. It is engineered to target the insulin-like growth factor 1 receptor (IGF-1R) to facilitate the transport of therapeutic payloads across the BBB via receptor-mediated transcytosis. This technology is intended to enable the delivery of drugs that are otherwise unable to penetrate the central nervous system, potentially addressing a wide range of neurological and neurodegenerative conditions.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on MVP-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP-106.

Explore the full profile